Al-Dawaa Medical Services Company (4163.SR)
SAR 78.9
(-0.63%)
SAR 78.9
(-0.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.74 Billion SAR | 6.87% |
| 2022 | 5.37 Billion SAR | 6.71% |
| 2021 | 5.03 Billion SAR | 1.46% |
| 2020 | 4.96 Billion SAR | 25.23% |
| 2019 | 3.96 Billion SAR | 4.35% |
| 2018 | 3.79 Billion SAR | 12.49% |
| 2017 | 3.37 Billion SAR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.51 Billion SAR | 4.0% |
| 2024 Q2 | 1.58 Billion SAR | 4.61% |
| 2023 Q2 | 1.43 Billion SAR | 2.07% |
| 2023 Q1 | 1.4 Billion SAR | -3.48% |
| 2023 FY | 5.74 Billion SAR | 6.87% |
| 2023 Q4 | 1.45 Billion SAR | 1.33% |
| 2023 Q3 | 1.43 Billion SAR | 0.15% |
| 2022 Q4 | 1.45 Billion SAR | 11.41% |
| 2022 Q3 | 1.3 Billion SAR | -0.1% |
| 2022 Q2 | 1.31 Billion SAR | 1.19% |
| 2022 Q1 | 1.29 Billion SAR | -0.27% |
| 2022 FY | 5.37 Billion SAR | 6.71% |
| 2021 Q3 | 1.25 Billion SAR | -0.57% |
| 2021 Q2 | 1.26 Billion SAR | 4.72% |
| 2021 Q4 | 1.29 Billion SAR | 3.08% |
| 2021 FY | 5.03 Billion SAR | 1.46% |
| 2021 Q1 | 1.2 Billion SAR | -2.52% |
| 2020 Q2 | 1.3 Billion SAR | 5.14% |
| 2020 FY | 4.96 Billion SAR | 25.23% |
| 2020 Q4 | 1.24 Billion SAR | 0.0% |
| 2020 Q3 | 1.24 Billion SAR | -4.82% |
| 2020 Q1 | 1.24 Billion SAR | 0.0% |
| 2019 FY | 3.96 Billion SAR | 4.35% |
| 2018 FY | 3.79 Billion SAR | 12.49% |
| 2017 FY | 3.37 Billion SAR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 338.43 Million SAR | -1596.422% |
| Nahdi Medical Company | 8.71 Billion SAR | 34.111% |
| Al-Razi Medical Co. | 61.33 Million SAR | -9260.844% |
| Almujtama Alraida Medical Co. | 407.73 Million SAR | -1308.096% |